'Serum won't have to take full loss': Bill Gates says his Foundation shares financial risk for vaccine
In his latest blog post, Bill & Melinda Gates Foundation co-chairman said his foundation has also taken some of the financial risks on the Oxford-AstraZeneca vaccine and that Serum won't have to take a full loss AstraZeneca Pharma gets DCGI nod to market asthma drug
Drug firm AstraZeneca Pharma on Monday said it has received marketing authorisation from the Drug Controller General of India for Benralizumab solutio ASTRAZENECA PHARMA INDIA LTD. - 506820 - Astrazeneca Pharma India Limited Receives Import And Market Permission In Form CT-20 (Marketing Authorization) From The Drugs Controller General Of India For Benralizumab 30Mg/Ml Solution For Injection (Fasenra(tm))
This is to inform that AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 (Marketing Authorization) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra(tm)). Benralizumab (Fasenra(tm)) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients. The receipt of this permission paves way for the launch of Benralizumab (Fasenra(tm)) in India, subject to the receipt of related statutory approvals and licenses.
Oxford/AstraZeneca vaccine set for clearance by year-end: Report
The Oxford/AstraZeneca, AZD1222, vaccine has taken longer for regulators to assess because of differences in the efficacy rates found in different groups, ranging from 62 to 90 percent. Two Doses Of Oxford/AstraZeneca Vaccine Prompts Good Immune Response: Early Data Reveals
Data published earlier from later Phase 3 trials showed efficacy was 62 per cent for trial participants given two full doses
COVID-19 vaccine | Oxford says its candidate has good immune response with two-dose regime
Oxford's vaccine candidate, which has been licensed to AstraZeneca, has published interim late stage trial results showing higher efficacy when a half dose is followed by a full dose, compared to a two full-dose regime, though more work needs to be done to affirm the result. Serum likely to submit final Covid-19 vaccine trial data in 10 days
If the data is found satisfactory, an approval for Covishield, Oxford-AstraZeneca's vaccine candidate, can come in by the first week of January ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated December 3, 2020 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Stuck in Sydney hotel, Astra CEO defended Covid vaccine and made mega deal
AstraZeneca announced Saturday it plans to buy rare-disease specialist Alexion Pharmaceuticals in a $39 billion deal AstraZeneca to purchase Alexion in $39 billion deal
The deal comes in a week that AstraZeneca said it was conducting further research to confirm whether its COVID-19 vaccine could be 90% effective, potentially slowing its rollout, and as a rival shot from Pfizer was launched in Britain and approved for use in the United States